Biocon Pushes to Unseal Amgen Eylea Court Filings Before Appeal

Amgen Inc. is “stonewalling” public access to information about its successful avoidance of Regeneron Pharmaceuticals Inc.’s bid to block its biosimilar of the blockbuster eye drug Eylea, two competitors said in a filing urging a judge to release a trove of sealed documents in the case.

Viatris Inc.'s Mylan Pharmaceuticals Inc. unit and Biocon Ltd., which will market Mylan’s biosimilar Yesafili in the US, urged Judge Thomas S. Kleeh to unseal the transcript for the Aug. 13 preliminary injunction hearing and related filings because keeping them sealed “improperly delays the public’s access to arguments that are set to be ...